Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Farmers Insurance
Federal Trade Commission
Chinese Patent Office
QuintilesIMS
Johnson and Johnson

Generated: August 20, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,670,386

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,670,386
Title: Bicyclic modulators of androgen receptor function
Abstract:The invention provides compounds of the formula I ##STR1## wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.
Inventor(s): Sun; Chongqing (East Windsor, NJ), Robl; Jeffrey A. (Newtown, PA), Salvati; Mark E. (Lawrenceville, NJ), Wang; Tammy (Lawrenceville, NJ), Hamann; Lawrence (Cherry Hill, NJ), Augeri; David (Princeton, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/209,461
Patent Claims:1. A compound of the formula I ##STR89##

wherein R.sub.1 is selected from the group consisting of hydrogen (H), cyano (--CN), nitro (--NO.sub.2), and halo; R.sub.2 is selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, arylalkyl or substituted arylalkyl, CO.sub.2 R.sub.5, CONR.sub.5 R.sub.5 ' and CH.sub.2 OR.sub.5 ; R.sub.3 is selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, halo, cyano(--CN), NHCOR.sub.5, NHCO.sub.2 R.sub.5, NHCONR.sub.5 R.sub.5 ', NHSO.sub.2 R.sub.5 and OR.sub.4 ; R.sub.4 in each functional group is independently selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, CHF.sub.2, CF.sub.3 and COR.sub.5 ; R.sub.5 and R.sub.5 ' in each functional group are each independently selected from the group consisting of hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, and --CN; W is (CR.sub.6 R.sub.6 '); R.sub.6 and R.sub.6 ' are each independently selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, halo, cyano (--CN), NHCOR.sub.5, NHCO.sub.2 R.sub.5, NHCONR.sub.5 R.sub.5 ', NHSO.sub.2 R.sub.5 and OR.sub.4 ; X is methylene (--CH.sub.2 --); Y is selected from the group consisting of oxygen(O), and sulfur(S); E is C.dbd.Z; Z is selected from the group consisting of oxygen(O), and sulfur(S); A and B are each independently selected from the group consisting of hydrogen (H), halo, cyano(--CN), nitro(--NO.sub.2), alkyl or substituted alkyl and OR.sub.4 ; n is an integer of 1; including all prodrug esters, pharmaceutically acceptable salts and stereoisomers thereof.

2. The compound as defined in claim 1 having the structure ##STR90##

3. The compound as defined in claim 2 wherein R.sub.1 is --NO.sub.2, --CN or halogen; R.sub.2 is hydrogen or C.sub.1 -C.sub.3 alkyl; R.sub.3 is hydrogen or hydroxyl (--OH); and n is an integer of 1.

4. The compound as defined in claim 1 having the structure ##STR91## ##STR92##

5. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.

6. The pharmaceutical composition of claim 5 further comprising a growth promoting agent.

7. A pharmaceutical composition comprising a compound as defined in claim 1 and at least one additional therapeutic agent selected from the group consisting of parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents, and thyroid mimetics.

8. A method for treating or delaying the progression or onset of muscular atrophy, lipodistrophy, long-term critical illness, sarcopenia, frailty or age-related functional decline, reduced muscle strength and function, reduced bone density or growth, the catabolic side effects of glucocorticoids, chronic fatigue syndrome, bone fracture repair, acute fatigue syndrome and muscle loss following elective surgery, cachexia, chronic catabolic state, eating disorders, side effects of chemotherapy, wasting, depression, nervousness, irritability, stress, growth retardation, reduced cognitive function, male contraception, hypogonadism, Syndrome X, diabetic complications or obesity, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in claim 1.

9. A method according to claim 8 further comprising administering, concurrently or sequentially, a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents, and thyroid mimetics.

10. A pharmaceutical composition capable of modulating the function of a nuclear hormone receptor, comprising a compound of formula I ##STR93##

wherein R.sub.1 is selected from the group consisting of hydrogen (H), cyano (--CN), nitro (--NO.sub.2), and halo; R.sub.2 is selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, arylalkyl or substituted arylalkyl, CO.sub.2 R.sub.5, CONR.sub.5 R.sub.5 ' and CH.sub.2 OR.sub.5 ; R.sub.3 is selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, halo, cyano(--CN), NHCOR.sub.5, NHCO.sub.2 R.sub.5, NHCONR.sub.5 R.sub.5 ', NHSO.sub.2 R.sub.5 and OR.sub.4 ; R.sub.4 in each functional group is independently selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, CHF.sub.2, CF.sub.3 and COR.sub.5 ; R.sub.5 and R.sub.5 ' in each functional group are each independently selected from the group consisting of hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, --CN; W is (CR.sub.6 R.sub.6 '); R.sub.6 and R.sub.6 ' are each independently selected from the group consisting of hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, halo, cyano (--CN), NHCOR.sub.5, NHCO.sub.2 R.sub.5, NHCONR.sub.5 R.sub.5 ', NHSO.sub.2 R.sub.5 and OR.sub.4 ; X is methylene (--CH.sub.2 --); Y is selected from the group consisting of oxygen(O), and sulfur(S); E is C.dbd.Z; Z is selected from the group consisting of oxygen(O), and sulfur(S); A and B are each independently selected from the group consisting of hydrogen (H), halo, cyano(--CN), nitro(--NO.sub.2), alkyl or substituted alkyl and OR.sub.4 ; n is an integer of 1; including all prodrug esters, pharmaceutically acceptable salts and stereoisomers thereof.

11. A pharmaceutical composition according to claim 10 wherein said nuclear hormone receptor is an androgen receptor.

Details for Patent 6,670,386

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2021-07-31 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2021-07-31 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2021-07-31 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23 ➤ Sign Up Bristol-Myers Squibb Company (Princeton, NJ) 2021-07-31 RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Fuji
US Department of Justice
Healthtrust
Fish and Richardson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.